デラウェア州におけるバーキットリンパ腫の臨床試験
デラウェア州内の拠点で、バーキットリンパ腫に関する7件の研究が参加者を募集しています。
公式研究テキスト（英語）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Alfred I duPont Hospital for Children, Wilmington
被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/02更新 · NCT06124157Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Alfred I duPont Hospital for Children, Wilmington
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Alfred I duPont Hospital for Children, Wilmington
被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Alfred I duPont Hospital for Children, Wilmington
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085Study of SGR-1505 in Mature B-Cell Neoplasms
- Christiana Care Hospital - Helen F Graham Cancer Center, Newark
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Alfred I. duPont Hospital for Children - Nemours Deleware, Wilmington
被験者募集中第2相
1歳〜25歳 · 全性別 · 2025/05/04更新 · NCT03509961ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。